Department of Pediatrics, Hacettepe University School of Medicine, Sihhiye, 06100, Ankara, Turkey.
Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Hacettepe University School of Medicine, Ankara, Turkey.
Ir J Med Sci. 2023 Dec;192(6):2735-2739. doi: 10.1007/s11845-023-03313-w. Epub 2023 Feb 27.
Parenteral nutrition may lead to inevitable complications.
To determine the indications, metabolic and mechanical complications of parenteral nutrition in children.
One hundred fifty-eight children (91 males; 57.8%) who received 179 episodes of individualized parenteral nutrition for ≥ 5 days within 2 years were analyzed. Indications and duration of parenteral nutrition, effect on growth, and metabolic and central venous catheter-related non-infectious complications were evaluated.
Parenteral nutrition was administered in 179 different episodes (109 males; 60.9%), and the median age during these episodes was 64.0 (14.0-129.0) months. The most common indications were hematological malignancies, gastrointestinal surgery, and hematopoietic stem cell transplantation. Most of the electrolyte imbalances occurred in the first 3 days. Hypophosphatemia (44.7%), hypomagnesemia (43.0%), hypokalemia (43.0%), hyponatremia (40.8%), and hypertriglyceridemia (38.2%) were the most common metabolic complications. Liver transaminases elevated in 32/145 (22.1%) episodes and bilirubin in 30/149 (21.0%). Ursodeoxycholic acid treatment was added to 25 patients with hypertransaminasemia and/or hyperbilirubinemia. Transaminase levels improved in 16 (64%) and bilirubin levels in 15 (60%) patients receiving ursodeoxycholic acid. Catheter thrombosis was seen in 4.5% of the episodes. The targeted energy could be given more efficiently via central catheters rather than peripheral venous accesses. Patients' bodyweights increased in 39.1% of the episodes.
Close monitoring of electrolyte levels, especially in the first 3 days, is crucial to prevent complications of parenteral nutrition. When individualized PN preparations are used for metabolically unstable patients, it can be easier to maintain the blood glucose, lipids, and electrolyte levels within the normal range.
肠外营养可能会导致不可避免的并发症。
确定儿童肠外营养的适应证、代谢和机械并发症。
分析了 158 例儿童(男 91 例,57.8%)在 2 年内接受了 179 次个体化肠外营养治疗,持续时间均≥5 天。评估了肠外营养的适应证和持续时间、对生长的影响,以及代谢和中心静脉导管相关的非感染性并发症。
179 个不同的肠外营养疗程(男 109 例,60.9%)中接受了肠外营养,这些疗程的中位年龄为 64.0(14.0-129.0)个月。最常见的适应证是血液系统恶性肿瘤、胃肠道手术和造血干细胞移植。大多数电解质失衡发生在第 3 天内。最常见的代谢并发症是低磷血症(44.7%)、低镁血症(43.0%)、低钾血症(43.0%)、低钠血症(40.8%)和高三酰甘油血症(38.2%)。32/145(22.1%)个疗程中肝转氨酶升高,30/149(21.0%)个疗程中胆红素升高。25 例高转氨酶血症和/或高胆红素血症患者加用熊去氧胆酸治疗。16 例(64%)患者的转氨酶水平改善,15 例(60%)患者的胆红素水平改善。4.5%的疗程中出现导管血栓形成。通过中心导管可以更有效地给予目标能量,而不是外周静脉通路。39.1%的疗程中患者体重增加。
密切监测电解质水平,特别是在前 3 天,对于预防肠外营养并发症至关重要。当对代谢不稳定的患者使用个体化 PN 制剂时,可以更容易地将血糖、血脂和电解质水平维持在正常范围内。